Physician profile
Brad Chesney
NPI 1912979139
$3,827.07
in general payments reported to CMS, 2019-2025
40 companies · $653 in 2025
The $653 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $378 · 2021: $418 · 2022: $662 · 2023: $723 · 2024: $570 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,942 · Gift: $4.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,942.07 |
| Gift | $4.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $861.84 | 2019-2023 | Orilissa, Lo Loestrin Fe, Ubrelvy |
| Astellas Pharma US INC | $409.62 | 2019-2025 | Veozah, Myrbetriq |
| Sage Therapeutics, LLC | $293.59 | 2024-2025 | Zurzuvae |
| Channel Medsystems, INC. | $250.75 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $246.24 | 2021-2025 | |
| Ascend Therapeutics US, LLC | $230.55 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.71 | 2019-2024 | |
| Organon LLC | $142.27 | 2022-2025 | Nexplanon |
| Stryker Corporation | $134.43 | 2022-2025 | 1788 |
| Pfizer INC. | $104.66 | 2023-2024 | |
| Daiichi Sankyo INC. | $98.97 | 2019-2022 | |
| Boston Scientific Corporation | $87.86 | 2022-2025 | Bulkamid - Bulkamid Urethral Bulking Pack 2ml (Ous) |
| Myriad Women'S Health, INC. | $87.55 | 2023 | Myrisk |
| Merck Sharp & Dohme LLC | $67.53 | 2019-2022 | |
| Intuitive Surgical, INC. | $62.03 | 2020-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Chesney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.